From Breakthrough to Blockbuster: The Business of Biotechnology by Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos

From Breakthrough to Blockbuster: The Business of Biotechnology
Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos
Page: 240
Format: pdf, ePub, mobi, fb2
ISBN: 9780195084009
Publisher: Oxford University Press
From Breakthrough to Blockbuster: The Business of Biotechnology

Book download guest From Breakthrough to Blockbuster: The Business of Biotechnology

Financial Times Business Top Title March 2022

How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries?

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources.

Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs.

From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets,
 and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.

Biotechnology - Business & Money: Books - Amazon.com
        From Breakthrough to Blockbuster: The Business of Biotechnology. by Donald L. Drakeman , Lisa N. Drakeman, et al. | Apr 29, 2022.
        From Breakthrough to Blockbuster: The Business  - WHSmith
        It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical 
        Amgen Inc.'s Epogen--Commercializing the First Biotech
        Amgen Inc.'s Epogen was the first biotech blockbuster drug. After a critical scientific breakthrough, which allowed Amgen to identify the EPO gene, 
        商品詳細（電子洋書 - 紀伊國屋書店
        From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports 
        New book highlights how small biotech  - AcademicGates
        From Breakthrough to Blockbuster: The Business of Biotechnology, published today, shows how the small, inexperienced entrepreneurial 
        From Breakthrough to Blockbuster - News & insight
        From Breakthrough to Blockbuster: The Business of Biotechnology, published today, shows how the small, inexperienced entrepreneurial 
        Best Biotech Stocks to Buy in 2022 | The Motley Fool
        Many of the best biotech companies have both strong drug If approved, AXS-05 as a depression treatment could be a blockbuster drug, 
        Business Of Biotechnology From The Bench To The Street
        IpoFrom Breakthrough to BlockbusterIntroduction to Biotech. Entrepreneurship: From Idea to BusinessThe Business of. BiotechnologyThe Business of Healthcare 
        From Breakthrough to Blockbuster (Hardcover) - Walmart.com
        This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs.

Items